Understanding ABECMA® (idecabtagene vicleucel)

Understanding ABECMA® (idecabtagene vicleucel) focuses on the first-in-class B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell immunotherapy approved by the U.S. Food and Drug Administration (FDA) for use in myeloma. Abecma (also known as "ide-cel") is the first CAR T-cell therapy to be approved by the FDA for patients with myeloma, and it is the first CAR T-cell therapy approved by the FDA that targets BCMA.